J&J has chosen a lead vaccine candidate that it began working on in January, but it likely won’t begin testing the vaccine on people until September.
After clinical trials, the first batches of a COVID-19 vaccine could be available for emergency use authorization early next year, J&J said.
The J&J effort will be funded in part by about $420 million from the Biomedical Advanced Research and Development Authority, which is part of the Office of the Assistant Secretary for Preparedness and Response at HHS.
J&J said the funding from the government will allow it to expand manufacturing capacity to make 1 billion doses of the vaccine.
Currently, there are no approved treatments or vaccines for COVID-19.
More articles on pharmacy:
Gilead asks FDA to take back orphan drug status for COVID-19 drug
Walmart nearly criminally charged over opioid prescriptions, report finds
13 drugmakers form consortium to find COVID-19 treatments
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
